Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2017

Open Access 01-12-2017 | Review

Pseudoxanthoma elasticum

Author: Dominique P. Germain

Published in: Orphanet Journal of Rare Diseases | Issue 1/2017

Login to get access

Abstract

Pseudoxanthoma elasticum (PXE) is a genetic metabolic disease with autosomal recessive inheritance caused by mutations in the ABCC6 gene. The lack of functional ABCC6 protein leads to ectopic mineralization that is most apparent in the elastic tissues of the skin, eyes and blood vessels. The clinical prevalence of PXE has been estimated at between 1 per 100,000 and 1 per 25,000, with slight female predominance. The first clinical sign of PXE is almost always small yellow papules on the nape and sides of the neck and in flexural areas. The papules coalesce, and the skin becomes loose and wrinkled. The mid-dermal elastic fibers are short, fragmented, clumped and calcified. Dystrophic calcification of Bruch’s membrane, revealed by angioid streaks, may trigger choroidal neovascularization and, ultimately, loss of central vision and blindness in late-stage disease. Lesions in small and medium-sized artery walls may result in intermittent claudication and peripheral artery disease. Cardiac complications (myocardial infarction, angina pectoris) are thought to be relatively rare but merit thorough investigation. Ischemic strokes have been reported. PXE is a metabolic disease in which circulating levels of an anti-mineralization factor are low. There is good evidence to suggest that the factor is inorganic pyrophosphate (PPi), and that the circulating low levels of PPi and decreased PPi/Pi ratio result from the lack of ATP release by hepatocytes harboring the mutant ABCC6 protein. However, the substrate(s) bound, transported or modulated by the ABCC6 protein remain unknown. More than 300 sequence variants of the ABCC6 gene have been identified. There is no cure for PXE; the main symptomatic treatments are vascular endothelial growth factor inhibitor therapy (for ophthalmic manifestations), lifestyle, lipid-lowering and dietary measures (for reducing vascular risk factors), and vascular surgery (for severe cardiovascular manifestations). Future treatment options may include gene therapy/editing and pharmacologic chaperone therapy.
Literature
1.
Darier J. Pseudoxanthoma elasticum. Monatshefte Prakt Derm. 1896;23:609–17.
2.
Rigal D. Observation pour servir à l’histoire de la cheloide diffuse xanthelasmique. Ann Dermatol Syph (Paris). 1881;2:491–501.
3.
Gronblad E. Angioid streaks - pseudoxanthoma elasticum. Acta Ophthal. 1929;7:329.CrossRef
4.
Strandberg J. Pseudoxanthoma elasticum. Z Haut Geschlechtskr. 1929;31:689.
5.
Le Saux O, Martin L, Aherrahrou Z, Leftheriotis G, Varadi A, Brampton CN. The molecular and physiological roles of ABCC6: more than meets the eye. Front Genet. 2012;3:289.PubMedPubMedCentral
6.
Li Q, Jiang Q, Uitto J. Ectopic mineralization disorders of the extracellular matrix of connective tissue: molecular genetics and pathomechanisms of aberrant calcification. Matrix Biol. 2014;33:23–8.PubMedCrossRef
7.
Jiang QU, Uitto J. Pseudoxanthoma elasticum: a metabolic disease? J Invest Dermatol. 2006;126:1440–1.PubMedCrossRef
8.
Jiang QEM, Dibra F, Wang K, Uitto J. Pseudoxanthoma elasticum is a metabolic disease. J Invest Dermatol. 2009;129:348–54.PubMedCrossRef
9.
Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Varadi A, et al. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014;34:1985–9.PubMedCrossRef
10.
Jansen RS, Kucukosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, et al. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A. 2013;110:20206–11.PubMedPubMedCentralCrossRef
11.
Hosen MJ, Lamoen A, De Paepe A, Vanakker OM. Histopathology of pseudoxanthoma elasticum and related disorders: histological hallmarks and diagnostic clues. Scientifica (Cairo). 2012;2012:598262.
12.
Jensen O. Bruch’s membrane in pseudoxanthoma elasticum. Histochemical, ultrastructural and x-ray microanalytical study of the membrane and angioid streak areas. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1977;203:311–20.PubMedCrossRef
13.
Walker ER, Frederickson RG, Mayes MD. The mineralization of elastic fibers and alterations of extracellular matrix in pseudoxanthoma elasticum. Ultrastructure, immunocytochemistry, and X-ray analysis. Arch Dermatol. 1989;125:70–6.PubMedCrossRef
14.
Struk B, Neldner KH, Rao VS, St Jean P, Lindpaintner K. Mapping of both autosomal recessive and dominant variants of pseudoxanthoma elasticum to chromosome 16p13.1. Hum Mol Genet. 1997;6:1823–8.PubMedCrossRef
15.
Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet. 2005;42:881–92.PubMedPubMedCentralCrossRef
16.
17.
Marconi B, Bobyr I, Campanati A, Molinelli E, Consales V, Brisigotti V, et al. Pseudoxanthoma elasticum and skin: Clinical manifestations, histopathology, pathomechanism, perspectives of treatment. Intractable Rare Dis Res. 2015;4:113–22.PubMedPubMedCentralCrossRef
18.
Lebwohl M, Lebwohl E, Bercovitch L. Prominent mental (chin) crease: a new sign of pseudoxanthoma elasticum. J Am Acad Dermatol. 2003;48:620–2.PubMedCrossRef
19.
Brown SJ, Talks SJ, Needham SJ, Taylor AE. Pseudoxanthoma elasticum: biopsy of clinically normal skin in the investigation of patients with angioid streaks. Br J Dermatol. 2007;157:748–51.PubMedCrossRef
20.
Van Loey S, Leys A. Pseudoxanthoma elasticum confirmed by genetic analysis but not by skin biopsy: a case report and review of the literature. Bull Soc Belge Ophtalmol. 2013;322:83–7.
21.
Lebwohl M, Schwartz E, Lemlich G, Lovelace O, Shaikh-Bahai F, Fleischmajer R. Abnormalities of connective tissue components in lesional and non-lesional tissue of patients with pseudoxanthoma elasticum. Arch Dermatol Res. 1993;285:121–6.PubMedCrossRef
22.
Contri MB, Boraldi F, Taparelli F, De Paepe A, Ronchetti IP. Matrix proteins with high affinity for calcium ions are associated with mineralization within the elastic fibers of pseudoxanthoma elasticum dermis. Am J Pathol. 1996;148:569–77.PubMedPubMedCentral
23.
Gheduzzi D, Sammarco R, Quaglino D, Bercovitch L, Terry S, Taylor W, et al. Extracutaneous ultrastructural alterations in pseudoxanthoma elasticum. Ultrastruct Pathol. 2003;27:375–84.PubMedCrossRef
24.
Georgalas I, Tservakis I, Papaconstaninou D, Kardara M, Koutsandrea C, Ladas I. Pseudoxanthoma elasticum, ocular manifestations, complications and treatment. Clin Exp Optom. 2011;94:169–80.PubMedCrossRef
25.
Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv Ophthalmol. 2003;48:424–38.PubMedCrossRef
26.
Orssaud C, Roche O, Dufier JL, Germain DP. Visual Impairment in Pseudoxanthoma Elasticum: A Survey of 40 Patients. Ophthalmic Genet. 2015;36:327–32.PubMedCrossRef
27.
Georgalas I, Papaconstantinou D, Koutsandrea C, Kalantzis G, Karagiannis D, Georgopoulos G, et al. Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag. 2009;5:81–9.PubMedPubMedCentral
28.
Plomp AS, Toonstra J, Bergen AA, van Dijk MR, de Jong PT. Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A. 2010;152A:1049–58.PubMedCrossRef
29.
Finger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HP, Holz FG, et al. The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum. Health Qual Life Outcomes. 2011;9:113.PubMedPubMedCentralCrossRef
30.
Leftheriotis G, Omarjee L, Le Saux O, Henrion D, Abraham P, Prunier F, et al. The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. Front Genet. 2013;4:4.PubMedPubMedCentralCrossRef
31.
Vanakker OM, Leroy BP, Coucke P, Bercovitch LG, Uitto J, Viljoen D, et al. Novel clinico-molecular insights in pseudoxanthoma elasticum provide an efficient molecular screening method and a comprehensive diagnostic flowchart. Hum Mutat. 2008;29:205.PubMedCrossRef
32.
Leftheriotis G, Abraham P, Le Corre Y, Le Saux O, Henrion D, Ducluzeau PH, et al. Relationship between ankle brachial index and arterial remodeling in pseudoxanthoma elasticum. J Vasc Surg. 2011;54:1390–4.PubMedCrossRef
33.
Iliopoulos J, Manganas C, Jepson N, Newman DC. Pseudoxanthoma elasticum: is the left internal mammary artery a suitable conduit for coronary artery bypass grafting? Ann Thorac Surg. 2002;73:652–3.PubMedCrossRef
34.
Lodge AJ, Dodd LG, Lowe JE. Arterial conduits should be evaluated preoperatively in coronary artery bypass patients with pseudoxanthoma elasticum. Tex Heart Inst J. 2005;32:576–8. discussion 8.PubMedPubMedCentral
35.
Zimmo L, Rudarakanchana N, Thompson M, Hamady MS, Cheshire NJ, Bicknell CD. Renal artery aneurysm formation secondary to pseudoxanthoma elasticum. J Vasc Surg. 2013;57:842–4.PubMedCrossRef
36.
van den Berg JS, Hennekam RC, Cruysberg JR, Steijlen PM, Swart J, Tijmes N, et al. Prevalence of symptomatic intracranial aneurysm and ischaemic stroke in pseudoxanthoma elasticum. Cerebrovasc Dis. 2000;10:315–9.PubMedCrossRef
37.
Vasseur M, Carsin-Nicol B, Ebran JM, Willoteaux S, Martin L, Leftheriotis G, et al. Carotid rete mirabile and pseudoxanthoma elasticum: an accidental association? Eur J Vasc Endovasc Surg. 2011;42:292–4.PubMedCrossRef
38.
Boutouyrie P, Germain DP, Tropeano AI, Laloux B, Carenzi F, Zidi M, et al. Compressibility of the carotid artery in patients with pseudoxanthoma elasticum. Hypertension. 2001;38:1181–4.PubMedCrossRef
39.
Germain DP, Boutouyrie P, Laloux B, Laurent S. Arterial remodeling and stiffness in patients with pseudoxanthoma elasticum. Arterioscler Thromb Vasc Biol. 2003;23:836–41.PubMedCrossRef
40.
Leftheriotis G, Kauffenstein G, Hamel JF, Abraham P, Le Saux O, Willoteaux S, et al. The contribution of arterial calcification to peripheral arterial disease in pseudoxanthoma elasticum. PLoS One. 2014;9:e96003.PubMedPubMedCentralCrossRef
41.
Debette S, Germain DP. Neurologic manifestations of inherited disorders of connective tissue. Handb Clin Neurol. 2014;119:565–76.PubMedCrossRef
42.
Karam C, Soulat G, Germain DP, Lacombe P, Dubourg O. Coronary CT angiography for chest pain in pseudoxanthoma elasticum and cardiac intervention management. J Cardiovasc Comput Tomogr. 2015;9:238–41.PubMedCrossRef
43.
Trip MD, Smulders YM, Wegman JJ, Hu X, Boer JM, ten Brink JB, et al. Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease. Circulation. 2002;106:773–5.PubMedCrossRef
44.
Goral V, Demir D, Tuzun Y, Keklikci U, Buyukbayram H, Bayan K, et al. Pseudoxantoma elasticum, as a repetitive upper gastrointestinal hemorrhage cause in a pregnant woman. World J Gastroenterol. 2007;13:3897–9.PubMedPubMedCentralCrossRef
45.
Pingel S, Passon SG, Pausewang KS, Blatzheim AK, Pizarro C, Tuleta I, et al. Pseudoxanthoma elasticum - also a lung disease? the respiratory affection of patients with Pseudoxanthoma elasticum. PLoS One. 2016;11:e0162337.PubMedPubMedCentralCrossRef
46.
Perdu J, Germain DP. Identification of novel polymorphisms in the pM5 and MRP1 (ABCC1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum. Hum Mutat. 2001;17:74–5.PubMedCrossRef
47.
Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet. 2000;25:228–31.PubMedCrossRef
48.
Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, et al. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet. 2000;25:223–7.PubMedCrossRef
49.
Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A. 2000;97:6001–6.PubMedPubMedCentralCrossRef
50.
Germain DP, Perdu J, Remones V, Jeunemaitre X. Homozygosity for the R1268Q mutation in MRP6, the pseudoxanthoma elasticum gene, is not disease-causing. Biochem Biophys Res Commun. 2000;274:297–301.PubMedCrossRef
51.
Struk B, Cai L, Zach S, Ji W, Chung J, Lumsden A, et al. Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum. J Mol Med (Berl). 2000;78:282–6.CrossRef
52.
Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011;50:179–207.PubMedCrossRef
53.
54.
Fulop K, Barna L, Symmons O, Zavodszky P, Varadi A. Clustering of disease-causing mutations on the domain-domain interfaces of ABCC6. Biochem Biophys Res Commun. 2009;379:706–9.PubMedCrossRef
55.
Aranyi T, Bacquet C, de Boussac H, Ratajewski M, Pomozi V, Fulop K, et al. Transcriptional regulation of the ABCC6 gene and the background of impaired function of missense disease-causing mutations. Front Genet. 2013;4:27.PubMedPubMedCentralCrossRef
56.
Ratajewski M, de Boussac H, Sachrajda I, Bacquet C, Kovacs T, Varadi A, et al. ABCC6 expression is regulated by CCAAT/enhancer-binding protein activating a primate-specific sequence located in the first intron of the gene. J Invest Dermatol. 2012;132:2709–17.PubMedPubMedCentralCrossRef
57.
de Boussac H, Ratajewski M, Sachrajda I, Koblos G, Tordai A, Pulaski L, et al. The ERK1/2-hepatocyte nuclear factor 4alpha axis regulates human ABCC6 gene expression in hepatocytes. J Biol Chem. 2010;285:22800–8.PubMedPubMedCentralCrossRef
58.
Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002;62:6172–7.PubMed
59.
Miksch S, Lumsden A, Guenther UP, Foernzler D, Christen-Zach S, Daugherty C, et al. Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutations in ABCC6. Hum Mutat. 2005;26:235–48.PubMedCrossRef
60.
Christen-Zach S, Huber M, Struk B, Lindpaintner K, Munier F, Panizzon RG, et al. Pseudoxanthoma elasticum: evaluation of diagnostic criteria based on molecular data. Br J Dermatol. 2006;155:89–93.PubMedCrossRef
61.
Pfendner EG, Vanakker OM, Terry SF, Vourthis S, McAndrew PE, McClain MR, et al. Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum. J Med Genet. 2007;44:621–8.PubMedPubMedCentralCrossRef
62.
Hornstrup LS, Tybjaerg-Hansen A, Haase CL, Nordestgaard BG, Sillesen H, Grande P, et al. Heterozygosity for R1141X in ABCC6 and risk of ischemic vascular disease. Circ Cardiovasc Genet. 2011;4:534–41.PubMedCrossRef
63.
Akoglu G, Li Q, Gokoz O, Gazyagci AS, Uitto J. Clinical and histopathological characteristics of a family with R1141X mutation of pseudoxanthoma elasticum - presymptomatic testing and lack of carrier phenotypes. Int J Dermatol. 2014;53:692–8.PubMedCrossRef
64.
Li Q, Grange DK, Armstrong NL, Whelan AJ, Hurley MY, Rishavy MA, et al. Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes. J Invest Dermatol. 2009;129:553–63.PubMedCrossRef
65.
Li Q, Aranyi T, Varadi A, Terry SF, Uitto J. Research progress in pseudoxanthoma elasticum and related ectopic mineralization disorders. J Invest Dermatol. 2016;136:550–6.PubMedPubMedCentralCrossRef
66.
Kuzaj P, Kuhn J, Michalek RD, Karoly ED, Faust I, Dabisch-Ruthe M, et al. Large-scaled metabolic profiling of human dermal fibroblasts derived from pseudoxanthoma elasticum patients and healthy controls. PLoS One. 2014;9:e108336.PubMedPubMedCentralCrossRef
67.
Hendig D, Langmann T, Kocken S, Zarbock R, Szliska C, Schmitz G, et al. Gene expression profiling of ABC transporters in dermal fibroblasts of pseudoxanthoma elasticum patients identifies new candidates involved in PXE pathogenesis. Lab Invest. 2008;88:1303–15.PubMedCrossRef
68.
Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999;59:175–82.PubMed
69.
Jiang Q, Oldenburg R, Otsuru S, Grand-Pierre AE, Horwitz EM, Uitto J. Parabiotic heterogenetic pairing of Abcc6−/−/Rag1−/− mice and their wild-type counterparts halts ectopic mineralization in a murine model of pseudoxanthoma elasticum. Am J Pathol. 2010;176:1855–62.PubMedPubMedCentralCrossRef
70.
Li Q, Kingman J, Uitto J. Mineral content of the maternal diet influences ectopic mineralization in offspring of Abcc6(−/−) mice. Cell Cycle. 2015;14:3184–9.PubMedPubMedCentralCrossRef
71.
Yoo JY, Blum RR, Singer GK, Stern DK, Emanuel PO, Fuchs W, et al. A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol. 2011;65:341–8.PubMedCrossRef
72.
Hendig D, Schulz V, Arndt M, Szliska C, Kleesiek K, Gotting C. Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clin Chem. 2006;52:227–34.PubMedCrossRef
73.
Suliman ME, Garcia-Lopez E, Anderstam B, Lindholm B, Stenvinkel P. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. Adv Clin Chem. 2008;46:217–62.PubMedCrossRef
74.
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81.PubMedCrossRef
75.
Lau WL, Liu S, Vaziri ND. Chronic kidney disease results in deficiency of ABCC6, the novel inhibitor of vascular calcification. Am J Nephrol. 2014;40:51–5.PubMedCrossRef
76.
Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013;19:217–26.PubMedCrossRef
77.
Mackay EW, Apschner A, Schulte-Merker S. Vitamin K reduces hypermineralisation in zebrafish models of PXE and GACI. Development. 2015;142:1095–101.PubMedCrossRef
78.
Kariminejad A, Bozorgmehr B, Najafi A, Khoshaeen A, Ghalandari M, Najmabadi H, et al. Retinitis pigmentosa, cutis laxa, and pseudoxanthoma elasticum-like skin manifestations associated with GGCX mutations. J Invest Dermatol. 2014;134:2331–8.PubMedCrossRef
79.
Jiang Q, Li Q, Grand-Pierre AE, Schurgers LJ, Uitto J. Administration of vitamin K does not counteract the ectopic mineralization of connective tissues in Abcc6 (−/−) mice, a model for pseudoxanthoma elasticum. Cell Cycle. 2011;10:701–7.PubMedPubMedCentralCrossRef
80.
Brampton C, Yamaguchi Y, Vanakker O, Van Laer L, Chen LH, Thakore M, et al. Vitamin K does not prevent soft tissue mineralization in a mouse model of pseudoxanthoma elasticum. Cell Cycle. 2011;10:1810–20.PubMedPubMedCentralCrossRef
81.
Gorgels TG, Waarsing JH, Herfs M, Versteeg D, Schoensiegel F, Sato T, et al. Vitamin K supplementation increases vitamin K tissue levels but fails to counteract ectopic calcification in a mouse model for pseudoxanthoma elasticum. J Mol Med (Berl). 2011;89:1125–35.CrossRef
82.
83.
Markello TC, Pak LK, St Hilaire C, Dorward H, Ziegler SG, Chen MY, et al. Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. Mol Genet Metab. 2011;103:44–50.PubMedPubMedCentralCrossRef
84.
De Vilder EY, Vanakker OM. From variome to phenome: Pathogenesis, diagnosis and management of ectopic mineralization disorders. World J Clin Cases. 2015;3:556–74.PubMedPubMedCentral
85.
Li Q, Price TP, Sundberg JP, Uitto J. Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations. Cell Cycle. 2014;13:2609–15.PubMedPubMedCentralCrossRef
86.
Szabo Z, Varadi A, Li Q, Uitto J. ABCC6 does not transport adenosine - relevance to pathomechanism of pseudoxanthoma elasticum. Mol Genet Metab. 2011;104:421. author reply 2.PubMedCrossRef
87.
Garcia-Fernandez MI, Gheduzzi D, Boraldi F, Paolinelli CD, Sanchez P, Valdivielso P, et al. Parameters of oxidative stress are present in the circulation of PXE patients. Biochim Biophys Acta. 2008;1782:474–81.PubMedCrossRef
88.
89.
Baccarani-Contri M, Bacchelli B, Boraldi F, Quaglino D, Taparelli F, Carnevali E, et al. Characterization of pseudoxanthoma elasticum-like lesions in the skin of patients with beta-thalassemia. J Am Acad Dermatol. 2001;44:33–9.PubMedCrossRef
90.
Hamlin N, Beck K, Bacchelli B, Cianciulli P, Pasquali-Ronchetti I, Le Saux O. Acquired Pseudoxanthoma elasticum-like syndrome in beta-thalassaemia patients. Br J Haematol. 2003;122:852–4.PubMedCrossRef
91.
Fabbri E, Forni GL, Guerrini G, Borgna-Pignatti C. Pseudoxanthoma-elasticum-like syndrome and thalassemia: an update. Dermatol Online J. 2009;15:7.PubMed
92.
Martin LJ, Lau E, Singh H, Vergnes L, Tarling EJ, Mehrabian M, et al. ABCC6 localizes to the mitochondria-associated membrane. Circ Res. 2012;111:516–20.PubMedPubMedCentralCrossRef
93.
94.
Rasmussen MS, M.; Moestrup, SK. Is classical pseudoxanthoma elasticum a consequence of hepatic ‘intoxication’ due to ABCC6 substrate accumulation in the liver? Expert Rev Endocr Metabol. 2013;8:37–46.
95.
Rasmussen MR, Nielsen KL, Laursen MR, Nielsen CB, Svendsen P, Dimke H, et al. Untargeted Metabolomics Analysis of ABCC6-Deficient Mice Discloses an Altered Metabolic Liver Profile. J Proteome Res. 2016;15:4591–600.PubMedCrossRef
96.
Li Q, Frank M, Thisse CI, Thisse BV, Uitto J. Zebrafish: a model system to study heritable skin diseases. J Invest Dermatol. 2011;131:565–71.PubMedCrossRef
97.
Li Q, Sadowski S, Frank M, Chai C, Varadi A, Ho SY, et al. The abcc6a gene expression is required for normal zebrafish development. J Invest Dermatol. 2010;130:2561–8.PubMedPubMedCentralCrossRef
98.
Li Q, Guo H, Chou DW, Berndt A, Sundberg JP, Uitto J. Mouse models for pseudoxanthoma elasticum: genetic and dietary modulation of the ectopic mineralization phenotypes. PLoS One. 2014;9:e89268.PubMedPubMedCentralCrossRef
99.
Gorgels TG, Hu X, Scheffer GL, van der Wal AC, Toonstra J, de Jong PT, et al. Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet. 2005;14:1763–73.PubMedCrossRef
100.
Klement JF, Matsuzaki Y, Jiang QJ, Terlizzi J, Choi HY, Fujimoto N, et al. Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol. 2005;25:8299–310.PubMedPubMedCentralCrossRef
101.
Heston WE, Vlahakis G. Mammary tumors, plaques, and hyperplastic alveolar nodules in various combinations of mouse inbred strains and the different lines of the mammary tumor virus. Int J Cancer. 1971;7:141–8.PubMedCrossRef
102.
Aherrahrou Z, Doehring LC, Ehlers EM, Liptau H, Depping R, Linsel-Nitschke P, et al. An alternative splice variant in Abcc6, the gene causing dystrophic calcification, leads to protein deficiency in C3H/He mice. J Biol Chem. 2008;283:7608–15.PubMedCrossRef
103.
Zhou Y, Jiang Q, Takahagi S, Shao C, Uitto J. Premature termination codon read-through in the ABCC6 gene: potential treatment for pseudoxanthoma elasticum. J Invest Dermatol. 2013;133:2672–7.PubMedPubMedCentralCrossRef
104.
Kauffenstein G, Pizard A, Le Corre Y, Vessieres E, Grimaud L, Toutain B, et al. Disseminated arterial calcification and enhanced myogenic response are associated with abcc6 deficiency in a mouse model of pseudoxanthoma elasticum. Arterioscler Thromb Vasc Biol. 2014;34:1045–56.PubMedPubMedCentralCrossRef
105.
Hosen MJ, Coucke PJ, Le Saux O, De Paepe A, Vanakker OM. Perturbation of specific pro-mineralizing signalling pathways in human and murine pseudoxanthoma elasticum. Orphanet J Rare Dis. 2014;9:66.PubMedPubMedCentralCrossRef
106.
Koblos G, Andrikovics H, Prohaszka Z, Tordai A, Varadi A, Aranyi T. The R1141X loss-of-function mutation of the ABCC6 gene is a strong genetic risk factor for coronary artery disease. Genet Test Mol Biomarkers. 2010;14:75–8.PubMedPubMedCentralCrossRef
107.
Pisciotta L, Tarugi P, Borrini C, Bellocchio A, Fresa R, Guerra D, et al. Pseudoxanthoma elasticum and familial hypercholesterolemia: a deleterious combination of cardiovascular risk factors. Atherosclerosis. 2010;210:173–6.PubMedCrossRef
108.
Sato N, Nakayama T, Mizutani Y, Yuzawa M. Novel mutations of ABCC6 gene in Japanese patients with Angioid streaks. Biochem Biophys Res Commun. 2009;380:548–53.PubMedCrossRef
109.
Li Q, Sadowski S, Uitto J. Angioid streaks in Pseudoxanthoma Elasticum: role of the p.R1268Q mutation in the ABCC6 gene. J Invest Dermatol. 2011;131:782–5.PubMedCrossRef
110.
Nitschke Y, Baujat G, Botschen U, Wittkampf T, du Moulin M, Stella J, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet. 2012;90:25–39.PubMedPubMedCentralCrossRef
111.
Kalal IG, Seetha D, Panda A, Nitschke Y, Rutsch F. Molecular diagnosis of generalized arterial calcification of infancy (GACI). J Cardiovasc Dis Res. 2012;3:150–4.PubMedPubMedCentralCrossRef
112.
Lebwohl M, Neldner K, Pope FM, De Paepe A, Christiano AM, Boyd CD, et al. Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol. 1994;30:103–7.PubMedCrossRef
113.
Larusso J, Ringpfeil F, Uitto J. Pseudoxanthoma elasticum: a streamlined, ethnicity-based mutation detection strategy. Clin Transl Sci. 2010;3:295–8.PubMedPubMedCentralCrossRef
114.
Le Saux O, Beck K, Sachsinger C, Silvestri C, Treiber C, Goring HH, et al. A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum. Am J Hum Genet. 2001;69:749–64.PubMedPubMedCentralCrossRef
115.
Jin L, Jiang Q, Wu Z, Shao C, Zhou Y, Yang L, et al. Genetic heterogeneity of pseudoxanthoma elasticum: the Chinese signature profile of ABCC6 and ENPP1 mutations. J Invest Dermatol. 2015;135:1294–302.PubMedPubMedCentralCrossRef
116.
117.
Pulkkinen L, Nakano A, Ringpfeil F, Uitto J. Identification of ABCC6 pseudogenes on human chromosome 16p: implications for mutation detection in pseudoxanthoma elasticum. Hum Genet. 2001;109:356–65.PubMedCrossRef
118.
Kringen MK, Stormo C, Grimholt RM, Berg JP, Piehler AP. Copy number variations of the ATP-binding cassette transporter ABCC6 gene and its pseudogenes. BMC Res Notes. 2012;5:425.PubMedPubMedCentralCrossRef
119.
Kringen MK, Stormo C, Berg JP, Terry SF, Vocke CM, Rizvi S, et al. Copy number variation in the ATP-binding cassette transporter ABCC6 gene and ABCC6 pseudogenes in patients with pseudoxanthoma elasticum. Mol Genet Genomic Med. 2015;3:233–7.PubMedPubMedCentralCrossRef
120.
Lewis KG, Bercovitch L, Dill SW, Robinson-Bostom L. Acquired disorders of elastic tissue: part I. Increased elastic tissue and solar elastotic syndromes. J Am Acad Dermatol. 2004;51:1–21. quiz 2–4.PubMedCrossRef
121.
Ibanez-Samaniego L, Ochoa-Palominos A, Catalina-Rodriguez MV, Salcedo-Plaza M, Clemente-Ricote G. Penicillamine induced pseudo-pseudoxanthoma elasticum in a patient with Wilson's disease, which role plays the hepatologist? Rev Esp Enferm Dig. 2015;107:190–1.PubMed
122.
Kazakis AM, Parish WR. Periumbilical perforating pseudoxanthoma elasticum. J Am Acad Dermatol. 1988;19:384–8.PubMedCrossRef
123.
Wang AR, Fonder MA, Telang GH, Bercovitch L, Robinson-Bostom L. Late-onset focal dermal elastosis: an uncommon mimicker of pseudoxanthoma elasticum. J Cutan Pathol. 2012;39:957–61.PubMedCrossRef
124.
Val-Bernal JF, Gonzalez-Vela MC, Leon-Castillo A, Armesto S. Papillary dermal elastosis. Am J Dermatopathol. 2017;39:150–2.PubMedCrossRef
125.
126.
Cianciulli P, Sorrentino F, Maffei L, Amadori S, Cappabianca MP, Foglietta E, et al. Cardiovascular involvement in thalassaemic patients with pseudoxanthoma elasticum-like skin lesions: a long-term follow-up study. Eur J Clin Invest. 2002;32:700–6.PubMedCrossRef
127.
Martin L, Douet V, VanWart CM, Heller MB, Le Saux O. A mouse model of beta-thalassemia shows a liver-specific down-regulation of Abcc6 expression. Am J Pathol. 2011;178:774–83.PubMedPubMedCentralCrossRef
128.
129.
Brenner B, Kuperman AA, Watzka M, Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost. 2009;35:439–46.PubMedCrossRef
130.
Li Q, Schurgers LJ, Smith AC, Tsokos M, Uitto J, Cowen EW. Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene. Am J Pathol. 2009;174:534–40.PubMedPubMedCentralCrossRef
131.
Vanakker OM, Martin L, Gheduzzi D, Leroy BP, Loeys BL, Guerci VI, et al. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol. 2007;127:581–7.PubMedCrossRef
132.
Viljoen DL, Bloch C, Beighton P. Plastic surgery in pseudoxanthoma elasticum: experience in nine patients. Plast Reconstr Surg. 1990;85:233–8.PubMedCrossRef
133.
Ng AB, O'Sullivan ST, Sharpe DT. Plastic surgery and pseudoxanthoma elasticum. Br J Plast Surg. 1999;52:594–6.PubMedCrossRef
134.
135.
Li Q, Jiang Q, Uitto J. Pseudoxanthoma elasticum: oxidative stress and antioxidant diet in a mouse model (Abcc6−/−). J Invest Dermatol. 2008;128:1160–4.PubMedCrossRef
136.
Verbraak FD. Antivascular endothelial growth factor treatment in pseudoxanthoma elasticum patients. Dev Ophthalmol. 2010;46:96–106.PubMedCrossRef
137.
Neri P, Salvolini S, Mariotti C, Mercanti L, Celani S, Giovannini A. Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br J Ophthalmol. 2009;93:155–8.PubMedCrossRef
138.
Myung JS, Bhatnagar P, Spaide RF, Klancnik Jr JM, Cooney MJ, Yannuzzi LA, et al. Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina. 2010;30:748–55.PubMedCrossRef
139.
Guo H, Li Q, Chou DW, Uitto J. Atorvastatin counteracts aberrant soft tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(−)/(−)). J Mol Med (Berl). 2013;91:1177–84.CrossRef
140.
Liew G, Mitchell P, Wong TY, Rochtchina E, Wang JJ. The association of aspirin use with age-related macular degeneration. JAMA Intern Med. 2013;173:258–64.PubMedCrossRef
141.
Li Q, Larusso J, Grand-Pierre AE, Uitto J. Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(−/−) mice-potential for treatment of pseudoxanthoma elasticum. Clin Transl Sci. 2009;2:398–404.PubMedPubMedCentralCrossRef
142.
Li Q, Uitto J. The mineralization phenotype in Abcc6 (−/−) mice is affected by Ggcx gene deficiency and genetic background--a model for pseudoxanthoma elasticum. J Mol Med (Berl). 2010;88:173–81.CrossRef
143.
Li Q, Sundberg JP, Levine MA, Terry SF, Uitto J. The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene. Cell Cycle. 2015;14:1082–9.PubMedPubMedCentralCrossRef
144.
Li Q, Kingman J, Sundberg JP, Levine MA, Uitto J. Dual effects of bisphosphonates on ectopic skin and vascular soft tissue mineralization versus bone microarchitecture in a mouse model of generalized arterial calcification of infancy. J Invest Dermatol. 2016;136:275–83.PubMedPubMedCentralCrossRef
145.
Pomozi V, Brampton C, Fulop K, Chen LH, Apana A, Li Q, et al. Analysis of pseudoxanthoma elasticum-causing missense mutants of ABCC6 in vivo; pharmacological correction of the mislocalized proteins. J Invest Dermatol. 2014;134:946–53.PubMedCrossRef
146.
Kolb PS, Ayaub EA, Zhou W, Yum V, Dickhout JG, Ask K. The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. Int J Biochem Cell Biol. 2015;61:45–52.PubMedCrossRef
147.
Le Saux O, Fulop K, Yamaguchi Y, Ilias A, Szabo Z, Brampton CN, et al. Expression and in vivo rescue of human ABCC6 disease-causing mutants in mouse liver. PLoS One. 2011;6:e24738.PubMedPubMedCentralCrossRef
148.
Pomozi V, Brampton C, Szeri F, Dedinszki D, Kozak E, van de Wetering K, et al. Functional rescue of ABCC6 deficiency by 4-phenylbutyrate therapy reduces dystrophic calcification in Abcc6−/− mice. J Invest Dermatol. 2017;137:595–602.PubMedCrossRef
149.
Aravalli RN, Steer CJ. Gene editing technology as an approach to the treatment of liver diseases. Expert Opin Biol Ther. 2016;16:595–608.PubMedCrossRef
150.
Chuah MK, Petrus I, De Bleser P, Le Guiner C, Gernoux G, Adjali O, et al. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol Ther. 2014;22:1605–13.PubMedPubMedCentralCrossRef
151.
Yokoo T, Kamimura K, Abe H, Kobayashi Y, Kanefuji T, Ogawa K, et al. Liver-targeted hydrodynamic gene therapy: Recent advances in the technique. World J Gastroenterol. 2016;22:8862–8.PubMedPubMedCentralCrossRef
152.
Brampton C, Aherrahrou Z, Chen LH, Martin L, Bergen AA, Gorgels TG, et al. The level of hepatic ABCC6 expression determines the severity of calcification after cardiac injury. Am J Pathol. 2014;184:159–70.PubMedPubMedCentralCrossRef
153.
Rothe M, Schambach A, Biasco L. Safety of gene therapy: new insights to a puzzling case. Curr Gene Ther. 2014;14:429–36.PubMedCrossRef
154.
Germain DP, Jurca-Simina IE. Principles of Human Genetics. In: Burlina AP, editor. Textbook of Treatable Neurometabolic Diseases. New York: Springer; 2017. In press.
155.
Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharmacol Ther. 2009;47:S111–7.PubMedCrossRef
156.
Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016;375:545–55.PubMedCrossRef
157.
158.
Uitto J, Li Q, van de Wetering K, Váradi A, Terry SF. Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016. J Invest Dermatol. 2017;137:790–5.PubMedCrossRef
159.
Hosen MJ, Van Nieuwerburgh F, Steyaert W, Deforce D, Martin L, Leftheriotis G, et al. Efficiency of exome sequencing for the molecular diagnosis of pseudoxanthoma elasticum. J Invest Dermatol. 2015;135:992–8.PubMedCrossRef
160.
Hendig D, Knabbe C, Gotting C. New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers. Front Genet. 2013;4:114.PubMedPubMedCentralCrossRef
Metadata
Title
Pseudoxanthoma elasticum
Author
Dominique P. Germain
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2017
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-017-0639-8

Other articles of this Issue 1/2017

Orphanet Journal of Rare Diseases 1/2017 Go to the issue

Research

Vineland adaptive behavior scales to identify neurodevelopmental problems in children with Congenital Hyperinsulinism (CHI)

Review

An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review

Research

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)

Letter to the Editor

Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union

Research

Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema

Research

Depression in patients with SAPHO syndrome and its relationship with brain activity and connectivity